BioNTech SE American Depositary Share
BNTX Real Time Price USDRecent trades of BNTX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by BNTX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
BNTX Revenue by Segment or Geography
New patents grants
-
Patent Title: Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy Apr. 08, 2025
-
Patent Title: Cytotoxic immunostimulating particles and uses thereof Apr. 01, 2025
-
Patent Title: Stable formulations of lipids and liposomes Feb. 11, 2025
-
Patent Title: Coronavirus vaccine Jan. 28, 2025
-
Patent Title: Coronavirus vaccine Jan. 07, 2025
-
Patent Title: Methods and compositions for stimulating immune response Dec. 17, 2024
-
Patent Title: Formulation for administration of rna Nov. 26, 2024
-
Patent Title: Coronavirus vaccine Nov. 05, 2024
-
Patent Title: Preparation and storage of liposomal rna formulations suitable for therapy Aug. 13, 2024
-
Patent Title: Stabilization of poly(a) sequence encoding dna sequences Aug. 06, 2024
-
Patent Title: Substituted imidazoquinolines Aug. 06, 2024
-
Patent Title: Substituted imidazoquinolines as agonists of tlr7 May. 21, 2024
-
Patent Title: Rna constructs and uses thereof Apr. 09, 2024
-
Patent Title: Monoclonal antibodies directed against programmed death-1 protein and their use in medicine Mar. 19, 2024
-
Patent Title: Coronavirus vaccine Mar. 12, 2024
-
Patent Title: Methods for characterizing loss of antigen presentation Mar. 05, 2024
-
Patent Title: Coronavirus vaccine Jan. 23, 2024
-
Patent Title: Method for reducing immunogenicity of rna Jan. 16, 2024
-
Patent Title: Nucleic acid molecules encoding binding agents to cd40 and 4-1bb (cd137) Nov. 14, 2023
-
Patent Title: Diagnosis and therapy of cancer involving cancer stem cells Oct. 24, 2023
-
Patent Title: Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases Oct. 17, 2023
-
Patent Title: Rna constructs and uses thereof Oct. 10, 2023
-
Patent Title: Human monoclonal antibodies to ganglioside gd2 Sep. 19, 2023
-
Patent Title: Rna for treatment of autoimmune diseases Jul. 18, 2023
-
Patent Title: Particles comprising a shell with rna May. 30, 2023
-
Patent Title: Coronavirus vaccine Jan. 10, 2023
-
Patent Title: Individualized vaccines for cancer Nov. 22, 2022
-
Patent Title: 3′-utr sequences for stabilization of rna Nov. 08, 2022
-
Patent Title: Methods and compositions for stimulating immune response Oct. 18, 2022
-
Patent Title: Preparation and storage of liposomal rna formulations suitable for therapy Jul. 26, 2022
-
Patent Title: Formulation for administration of rna May. 03, 2022
-
Patent Title: Recombinant vaccines and use thereof Apr. 12, 2022
-
Patent Title: Predicting immunogenicity of t cell epitopes Jan. 11, 2022
-
Patent Title: Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof Jun. 29, 2021
-
Patent Title: Cytotoxic immunostimulating particles and uses thereof Apr. 20, 2021
-
Patent Title: Agonistic tumor necrosis factor (tnf) receptor binding agents Feb. 23, 2021
-
Patent Title: Particles comprising protamine and rna in combination with endosome destabilizing agents Aug. 04, 2020
-
Patent Title: Agents for treatment of claudin expressing cancer diseases Jul. 21, 2020
-
Patent Title: Hydrogen water generator May. 26, 2020
-
Patent Title: Methods of inducing t cell activation by administering an antibody comprising cd40 and 4-1bb (cd137) binding domains Oct. 29, 2019
-
Patent Title: Compositions and methods for diagnosis and treatment of cancer Aug. 06, 2019
-
Patent Title: Identification of surface-associated antigens for tumor diagnosis and therapy May. 28, 2019
-
Patent Title: Identification of tumor-associated markers for diagnosis and therapy Apr. 09, 2019
-
Patent Title: Tumor antigens for determining cancer therapy Jan. 29, 2019
-
Patent Title: Particles comprising single stranded rna and double stranded rna for immunomodulation Jan. 08, 2019
-
Patent Title: Modification of rna, producing an increased transcript stability and translation efficiency Oct. 23, 2018
-
Patent Title: Agents for treatment of claudin expressing cancer diseases Oct. 09, 2018
-
Patent Title: Site-specific antibody-mediated activation of proapoptotic cytokines: amaize (antibody-mediated apoptosis inducing cytokines) Apr. 17, 2018
-
Patent Title: Identification of tumor-associated cell surface antigens for diagnosis and therapy Mar. 06, 2018
-
Patent Title: Homo- and heterodimeric smac mimetic compounds as apoptosis inducers Aug. 15, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to BNTX
Recent picks made for BNTX stock on CNBC
ETFs with the largest estimated holdings in BNTX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $BNTX stock a Buy, Sell, or Hold?
- What is the price target for $BNTX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $BNTX stock?
- Who owns the most shares of $BNTX stock?
- What funds own $BNTX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BNTX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.